Your browser doesn't support javascript.
loading
Response to crizotinib in a patient with MET-amplified hepatocellular carcinoma.
Chen, Qinglian; Xie, Chunfeng; Feng, Kunliang; Huang, Haijun; Xiong, Chengming; Lin, Tengjiao; Wang, Wenjing; Xu, Mian; Yang, Xianwei; Zhong, Chong.
Affiliation
  • Chen Q; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Xie C; Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Feng K; The First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Huang H; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Xiong C; Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Lin T; The First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Wang W; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Xu M; Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Yang X; The First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Zhong C; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Hepatol Res ; 51(11): 1164-1169, 2021 Nov.
Article in En | MEDLINE | ID: mdl-33991153
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Hepatol Res Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Hepatol Res Year: 2021 Document type: Article